chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Fatigue; nausea; light headedness; pain at injection site; This is a spontaneous report from a contactable other healthcare professional reported for a 50-year-old male patient received first dose BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number: not reported) intramuscularly on 28Jan2021 at single dose for COVID-19 immunization. The patient medical history and concomitant medications were not reported. Patient has not received any other vaccines within 4 weeks prior to the COVID vaccine. The patient experienced fatigue, nausea, light headedness, pain at injection site after vaccination on 28Jan2021. No treatment received for the adverse events. Patient was not diagnosed with COVID-19 prior to vaccination. Patient has not been tested for COVID-19 since having the vaccine. The outcome of events fatigue, nausea, light headedness, pain at injection site was recovering.  No follow-up attempts are possible, Information on the lot/batch number has been requested.
someone who has gotten the rash after the COVID shot, but it was after the second shot; This is a spontaneous report from a contactable consumer or other non hcp. A patient of unspecified age and gender received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Lot number was not reported), dose 2 via an unspecified route of administration on an unspecified date as dose 2, single for covid-19 immunisation. The patient medical history and concomitant medications were not reported. Reporter mentioned that week she has talked to a couple of people and they indicate they know someone who has gotten the rash after the COVID shot, but it was after the second shot on an unspecified date. The outcome of the event was unknown.  Information about lot/batch number has been requested.  Follow-up (12May2021): Follow-up attempts completed. No further information expected.
pain at injection site, headache, muscle cramps and pain, joint pain, nausea, chills all started about 8 hours after the injection and are still ongoing.
Large red pruritic hive to right deltoid.  Large pruritic hive to left torso and back.  Onset with 24 hours of injection, lasted 2-3 days.  Resolved with Benadryl.
Swollen tongue/throat, numbness in arm/leg/jaw, rapid heart beat.  Treated with  Benadryl upon onset.  Followed with Claritin day 3 to present.
had difficulty with all of the shots; This spontaneous case was reported by an other health care professional and describes the occurrence of VACCINATION COMPLICATION (had difficulty with all of the shots) in a 55-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 042L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 20-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced VACCINATION COMPLICATION (had difficulty with all of the shots). At the time of the report, VACCINATION COMPLICATION (had difficulty with all of the shots) outcome was unknown.        mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosing remained unchanged.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications were reported.  No known allergies were reported.  No treatment medications were reported.   This case was linked to MOD-2022-538666, MOD-2022-538668 (Patient Link).
A couple of weeks after receiving my third dose, I experienced congestion and having pain/pressure in my ear. This lasted for about a month. I went to the doctor to get some medication. I was given prednisone and possibly doxycycline. I also started to experiencing a flare up with my Rheumatoid arthritis. I have not had a flare up for about three years. As of today, I am feeling much better. I'm still on a small dose of prednisone because of the flare up. I have been referred to an ENT, but I couldn't get in for a couple of weeks. By the time I could get in there, the pressure/pain was gone.
I developed a painful red rash 4cm x4cm on my left upper arm just below my vaccination site.  It lasted about 3 days before completly resolving.
Fever, chills, sore throat, headache, nausea, muscle pain, fatigue and joint pains.
(L) thigh red & swollen, warm to touch (4.5 in x 2.5 in).
No adverse event; Dose given after the published expiration date on 19MAY2023. Lot number 061F22A, expiration date 16MAY2023; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Dose given after the published expiration date on 19MAY2023. Lot number 061F22A, expiration date 16MAY2023) and NO ADVERSE EVENT (No adverse event) in a 30-year-old male patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 061F22A) for COVID-19 prophylaxis.     Previously administered products included for Product used for unknown indication: Tdap and Hepatitis B (booster). Past adverse reactions to the above products included No adverse event with Hepatitis B and Tdap.    On 19-May-2023, the patient received fourth dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 19-May-2023,  after starting mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)), the patient experienced EXPIRED PRODUCT ADMINISTERED (Dose given after the published expiration date on 19MAY2023. Lot number 061F22A, expiration date 16MAY2023). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Dose given after the published expiration date on 19MAY2023. Lot number 061F22A, expiration date 16MAY2023) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (Dose given after the published expiration date on 19MAY2023. Lot number 061F22A, expiration date 16MAY2023).    It was reported that patient received other vaccines 4 weeks prior to Covid-19 vaccine.  Concomitant product use was not provided by the reporter.  It was reported that dose was given after the published expiration date on 19MAY2023. Lot number 061F22A, expiration date 16MAY2023. No reported symptoms. No additional doses, medications, or treatments.  Treatment information was not provided.
1/26/2021 vaccination 1/27  I got up to breast feed daughter, I could tell I was achy, chills, sweating. Progressed as day went on. Lasted for approximately 3 days.  Sore arm, raised welt on arm at injection site. Sore throat, my lymph nodes were swollen.  * 1/8 COVID +
Patient received immunization and while walking around the store about 10 minutes later said her head hurt then fainted
She came to report a very intense bruise that is painful on her arm. It started after she got the injection on 8/26/18.
Patient honked horn to alert medical team needed assistance. When medical team arrived to vehicle patient was unresponsive but breathing and had a pulse. Patient was given EPIPEN by APN. Within 2 minutes patient began to arouse and could state her name and where she was.  She stated at times she has syncopal episodes.  BP, HR, all monitored. EMS notified and arrived at scene.  Patient checked by EMS but declined to be transported to the hospital.  Patient husband came and took her home.
developed a rash; This case was reported by a consumer via interactive digital media and described the occurrence of rash in a 59-year-old patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, 3 days after receiving Shingrix, the patient experienced rash. On an unknown date, the outcome of the rash was unknown.   It was unknown if the reporter considered the rash to be related to Shingrix.     Additional Information: GSK receipt date :27-OCT-2022 Reporters comment: This case was reported by a consumer via interactive digital media. The patient received first dose of shingrix vaccine and experienced rash after 3 days of vaccination . The patient stated that he/she did not had any conditions to compromise immunity and asked for the second shot.
Swelling, soreness 16 hours later, low grade fever 24 hours later.
This spontaneous report as received from a physician refers to a patient of unknown age and gender. On 29-OCT-2013 the patient was vaccinated with GARDASIL 120 Y (dose number, dose, route of administration unknown). Pertinent medical history and concomitant medications were unknown. The reporter stated that on an unknown date the patient would like to receive the subsequent doses in the series now. No adverse symptoms were reported. The outcome of the event was unknown. No further information provided. Additional information has been requested.
Hives all over body starting 2/3/17 and worsening 2/6/17.
Pt given flu vaccine instead of covid vaccine.  Pt had already received flu vaccine. No ill effects noted.
I woke up early 14Jan2021 with some minor heart palpitations/they got more frequent and lasted longer (had one about every hour and half and they lasted 20 to 30 minutes); I woke up early 14Jan2021 with some minor heart palpitations/they got more frequent and lasted longer (had one about every hour and half and they lasted 20 to 30 minutes); just fatigued the rest of the day; This is a spontaneous report from a contactable consumer. A 73-year-old male patient received the first dose  of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, lot: EL3246), via an unspecified route of administration in the left arm on 13Jan2021 12:45 at a single dose for covid-19 immunization. The patient's medical history included borderline prehypertension from an unknown date and unknown if ongoing. Concomitant medication included dexlansoprazole (DEXILANT) and enalapril maleate (ENALAPRIL MALEATE). The patient previously took anticoagulant citrate dextrose and experienced drug hypersensitivity. After the patient received the vaccine, the patient felt OK, just fatigued the rest of the day, nothing out of the ordinary for a vaccination. Patient woke up early in 14Jan2021, 06:00 with some minor heart palpitations. As the day progressed, they got more frequent and lasted longer (had one about every hour and half and they lasted 20 to 30 minutes). By the evening of 14Jan2021 he told his wife about the problem. In the morning of 15Jan2021 it's still occurring but not as frequently, but they did last just as long. By evening they were less frequent and lasting quite a bit shorter (10 to 15 minutes). On 16Jan2021, it only happened about a dozen times and lasted less than 5 minutes. On 17Jan2021, he only had a couple of occurrences. Today (18Jan2021), by 12:45 PM, patient  have had only 2 occurrences. The outcome of the events was recovering. The patient did not have Covid prior to vaccination and was not tested positive prior and post vaccination.
Severe pain next day left arm; Headache; Fatigue; Skin peeling near injection site; Chills, shivers; Burning sensation entire body; Itching; Rash; Difficulty breathing; Swelling at injection site to the point the band aid cut into the skin; Fever; This is a spontaneous report from a non-contactable consumer, the patient. A 31-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: FC3183) via an unspecified route of administration in the left arm on 31Aug2021 at 17:00 (at the age of 31-year-old) as a single dose for COVID-19 immunisation. Medical history included post-traumatic stress disorder (PTSD), fibromyalgia, scoliosis, chronic pain, hypermobility syndrome, allergic rhinitis, underweight, peanut allergy and allergy nos (unidentified). Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medication included ascorbic acid/betacarotene/biotin/calcium carbonate/calcium pantothenate/chromic chloride/colecalciferol/cupric oxide/cyanocobalamin/dl-alpha tocopheryl acetate/ferrous fumarate/folic acid/magnesium oxide/manganese sulfate/nicotinamide/phytomenadione/pyridoxine hydrochloride/retinol acetate/riboflavin/sodium selenate/thiamine mononitrate/zinc oxide (ONE A DAY MULTIVITAMINS MINI GELS WOMEN'S) from an unknown date for unknown indication and unknown if ongoing. The patient previously received amoxicillin (MANUFACTURER UNKNOWN) and azithromycin (AZO); both for unknown indications on unknown dates and experienced drug allergy. On 31Aug2021 at 19:00, the patient experienced skin peeling near injection site, chills, shivers, burning sensation entire body, itching, rash, difficulty breathing, swelling at injection site to the point the band aid cut into the skin, fever, severe pain next day (on 01Sep2021) in left arm, headache and fatigue. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were taken as a result of the reported events and included treatment with diphenhydramine hydrochloride (BENADRYL) and observation by special order (SO) and advice from nurse. The clinical outcome of the events skin peeling near injection site, chills, shivers, burning sensation entire body, itching, rash, difficulty breathing, swelling at injection site to the point the band aid cut into skin, fever, severe pain next day left arm, headache and fatigue was resolving at the time of this report.  No follow-up attempts are possible. No further information is expected.
Mollusccum contagiosum; This spontaneous case was reported by a consumer and describes the occurrence of MOLLUSCUM CONTAGIOSUM (Mollusccum contagiosum) in a 58-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 047A21A) for COVID-19 vaccination.     Concurrent medical conditions included Cholesterol.    On 30-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 02-Apr-2021, the patient experienced MOLLUSCUM CONTAGIOSUM (Mollusccum contagiosum). The patient was treated with EZETIMIBE ongoing since an unknown date at a dose of 1 dosage form; PANTOPRAZOLE ongoing since an unknown date at a dose of 1 dosage form; IBUPROFEN ongoing since an unknown date at a dose of 1 dosage form and COLCHICINE ongoing since an unknown date at a dose of 1 dosage form. At the time of the report, MOLLUSCUM CONTAGIOSUM (Mollusccum contagiosum) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   This case was linked to MOD-2021-177290 (Patient Link).
after my second shot on tuesday i got up wednesday  and went to the dr.ortopedic surgeny i came home had the chills my wife took me to the emergeny room  i went to give them a urine sample i stood up in the restroom and fell on my face i had nofeelins in my legs they ran all these test couldn't fine anything i went home and when to bed got up the next dayfelst great.
COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from a non-contactable reporter(s) (Other HCP). The reporter is the patient.  A 24-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 10Oct2021 as dose 3, single (Lot number: FF2593) at the age of 23 years for covid-19 immunisation. The patient's relevant medical history included: "Crohn's disease" (unspecified if ongoing); "hypothyroidism" (unspecified if ongoing). Concomitant medication(s) included: LEVOTHYROXINE; BUDESONIDE; ALYACEN. Vaccination history included: covid-19 vaccine (Dose 1, Single, Lot No. EL9261), administration date: 23Jan2021, for Covid-19 immunisation; covid-19 vaccine (Dose 2, Single, Lot No. EL9261), administration date: 15Feb2021, for Covid-19 immunisation. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "COVID 19 Treatment". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Positive; Negative. Therapeutic measures were taken as a result of drug ineffective, covid-19.  No follow-up attempts are possible. No further information is expected.; Sender's Comments: Based on reported information, causal association of event drug ineffective, covid-19 with BNT162b2 cannot be excluded. However, response to vaccine can vary in individuals.
Pt received his first dose of the pedi pfizer covid19 vaccine, while sitting in observation for his 15 minutes he was observed scratching at the injection site.  Injection site evaluated by RN and found to be red with splotches. Pt's pediatrician was on site and evaluated the pt's arm. Pt was not experiencing any other signs of allergy. Per pediatrician it was a localized reaction, pt waited in observation for an additional 30 minutes. EMS on site if needed. Symptoms did not progress, rash decreased in redness, pt stopped scratching. Mom was advised on ED precautions and when to call 911 to which mom verbalized understanding and agreed to the POC. Pt was sent home.
after 15 minute wait after Covid 19, pt got off exam table and her vision became black and her head started to hurt.  Immediatley went back on exam table.  Skin warm and dry,  HR 84  B/P 124/82 @ 4:55 pm.  Given sips of juice. Some nausea with sips.       Allowed to rest but after 10 minutes got assistance from RN.  Pt with history of migraines.  VS monitored and stable   5:10 pm 126/81  Pulse 81   5 :15 pm 143/85 Pulese 81 pulse Ox 99  5:20 pm one 500 mg Tylenol PO given per verbal order          Blackness to vision subsided, headache remained   5:24 pm 130/91 pulse 88    Pulse Ox 100  - pt now sitting up.  5:26 pm   131/87   pulse 92  POX 100  sitting on side of table.  5:30 pm   115/80   pulse 90  POX 99  Head ache subsiding, Able to stand at side of table without dizziness or black vision.     RN discussed options for further eval, family declined at this time.  Pt now able  tolerate standing without dizziness, black vision and headache continuing to improve.       Discharged home with care from sister.  Instructions to seek emergency treatment for return or worsening symptoms.  Sister voiced understanding.
body aches; slight fever (<100 degrees); headache; This is a spontaneous report from a contactable consumer (parent) or other non hcp.   An 18-year-old female (Non pregnant) patient received second dose of bnt162b2 (Pfizer-BioNTech COVID-19 Vaccine, solution for injection, Batch/Lot number EP6955) via an unspecified route of administration, administered in left arm, on 12Apr2021 11:15 (age at vaccination 18 year) as dose 2, single for covid-19 immunization. The patient medical history and concomitant medications were not reported. Historical vaccine included first dose of bnt162b2 (Pfizer-BioNTech COVID-19 Vaccine, solution for injection, Batch/Lot number EP6955) via an unspecified route of administration, administered in left arm, on 22Mar2021 12:15 (age at vaccination 18 year) as dose 1, single for covid-19 immunization. The patient was not received any other vaccines within 4 weeks prior to the COVID-19 vaccine. The patient was not received any other medications within 2 weeks of vaccination. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient was not tested for COVID-19. On 13Apr2021 at 09:00, the patient experienced slight fever (<100 degrees), body aches, headache. The patient underwent lab tests and procedures which included body temperature: <100 fahrenheit (slight fever (<100 degrees) on 13Apr2021. The patient was not received treatment for the adverse events. The outcome of the slight fever (<100 degrees), body aches, headache was recovering.  No follow-up attempts are needed. No further information is expected.
Extremely high fever, 104° for prolonged hours causing nausea, vomiting, and extreme exhaustion and chills
about 24hrs p/vax pt cried non-stop for 3hrs/fever 103 ax & whined for 24hrs p/that
Very sore arm, also got black & blue as of 8-18-11 arm still sore & black & blue, bleed thru bandage & onto my top.
Starting late 10/18/16 pain in back radiating to ribs only on right side; worsened on 10/19/16 and had fever 100 degrees F; difficulty sitting, laying down due to pain intensity; peak 11 PM 10/19/16; start resolve AM 10/20/16 as fever breaks; no pain by 10/21/16; treated with: Aspirin, ICY HOT Back Patches and Cold Packs.
Pain in the injection arm/soreness in the injection arm; Upset Stomach; "Felt like I had the Flu"; Joint Pain/Joint Ache; Tiredness; Nausea; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Pain in the injection arm/soreness in the injection arm), ABDOMINAL DISCOMFORT (Upset Stomach), INFLUENZA LIKE ILLNESS ("Felt like I had the Flu"), ARTHRALGIA (Joint Pain/Joint Ache) and FATIGUE (Tiredness) in a 53-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 026A21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included Sinus infection (Received treatment for sinus infection before getting the vaccine.). Concomitant products included FLUTICASONE PROPIONATE (FLONASE [FLUTICASONE PROPIONATE]), FLUTICASONE PROPIONATE (FLOVENT), SALBUTAMOL, CITALOPRAM and BUPROPION HYDROCHLORIDE (WELLBUTRIN) for an unknown indication.    On 11-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 11-Mar-2021, the patient experienced PAIN IN EXTREMITY (Pain in the injection arm/soreness in the injection arm), ABDOMINAL DISCOMFORT (Upset Stomach), INFLUENZA LIKE ILLNESS ("Felt like I had the Flu"), ARTHRALGIA (Joint Pain/Joint Ache), FATIGUE (Tiredness) and NAUSEA (Nausea). The patient was treated with PARACETAMOL (TYLENOL) at an unspecified dose and frequency. At the time of the report, PAIN IN EXTREMITY (Pain in the injection arm/soreness in the injection arm), ABDOMINAL DISCOMFORT (Upset Stomach), INFLUENZA LIKE ILLNESS ("Felt like I had the Flu"), ARTHRALGIA (Joint Pain/Joint Ache), FATIGUE (Tiredness) and NAUSEA (Nausea) was resolving.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.